Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly crawled date : 2021 - 04 - 20 save search
Reify Health Powers Patient Recruitment and Enrollment Across AstraZeneca’s Extensive Breast Cancer Clinical Trial Pipeline
Published: 2021-04-20 (Crawled : 18:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.89%
H: 0.5%
C: 0.35%
cancer breast cancer trial enroll health
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in...
Published: 2021-04-20 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: -1.04%
H: 4.22%
C: 3.4%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
covid antiviral research covid-19
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
Published: 2021-04-20 (Crawled : 15:15) - biospace.com/
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: -1.04%
H: 4.22%
C: 3.4%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
covid antiviral research covid-19
2021 COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
Published: 2021-04-20 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: -1.04%
H: 4.22%
C: 3.4%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
covid antiviral research covid-19
Reviews of Pediatric Studies Conducted under BPCA and PREA from 2012 – present
Published: 2021-04-20 (Crawled : 13:17) - fda.gov
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.46%
H: 1.26%
C: 0.72%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.23%
H: 1.65%
C: 0.96%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.45%
H: 1.33%
C: 0.84%
XERS | $1.73 -1.7% -1.73% 2M
|
Health Technology
|
| O: -0.8%
H: 3.24%
C: 2.97%
SNY | News | $46.385 2.19% 3M
|
Health Technology
|
| O: -0.08%
H: 0.42%
C: 0.42%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.03%
H: 1.44%
C: 0.97%
OTIC | $0.077
|
Health Technology
|
| O: 0.0%
H: 0.86%
C: -1.72%
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: -0.83%
H: 4.52%
C: 3.46%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 1.22%
C: 0.88%
BCRX | $4.44 -1.33% -1.35% 4.7M
|
Health Technology
|
| O: -0.17%
H: 3.22%
C: -3.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.44%
H: 2.17%
C: 1.69%
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Published: 2021-04-20 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.28%
H: 2.1%
C: 2.01%
growth phase 3 hair regrowth baricitinib
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Published: 2021-04-20 (Crawled : 09:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 1.62%
C: 0.11%
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 1.01%
C: 0.79%
growth
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.